Esculetin (dihydroxycoumarin) inhibits the production of matrix metalloproteinases in cartilage explants, and oral administration of its prodrug, CPA-926, suppresses cartilage destruction in rabbit experimental osteoarthritis

Journal of Rheumatology

Volumn 26, Issue 3, 1999, Pages 654-662

  Yamada, Harumoto ^a,e   Watanabe, Koju ^b   Saito, Tsuyoshi ^b   Hayashi, Haruhisa ^b   Niitani, Yoshiaki ^b   Kikuchi, Toshiyuki ^a   Ito, Akira ^c   Fujikawa, Kyosuke ^a   Stefan Lohmander, L ^d  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b KUREHA CORPORATION   (Japan)

^c TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Animal model; Cartilage; Coumarin derivative; Esculetin; Matrix metalloproteinases; Osteoarthritis

Indexed keywords

1,9 DIMETHYLMETHYLENE BLUE; 6 [[2 (ACETYLAMINO) 2 DEOXY BETA DEXTRO GLUCOPYRANOSYL] OXY] 7 HYDROXYCOUMARIN; COLLAGEN; COLLAGENASE; CPA 926; DYE; ENZYME PRECURSOR; ESCULETIN; MATRIX METALLOPROTEINASE; PRODRUG; PROTEOGLYCAN; RECOMBINANT INTERLEUKIN 1ALPHA; STROMELYSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARTILAGE DEGENERATION; COLLAGEN DEGRADATION; CONTROLLED STUDY; DRUG STRUCTURE; EXPLANT; IN VITRO STUDY; IN VIVO STUDY; KNEE OSTEOARTHRITIS; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; SYNOVIAL FLUID;

ADMINISTRATION, ORAL; ANIMALS; BLOTTING, WESTERN; CARTILAGE, ARTICULAR; COLLAGENASES; COUMARINS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ENZYME PRECURSORS; INTERLEUKIN-1; JOINTS; MALE; MATRIX METALLOPROTEINASE 1; METALLOENDOPEPTIDASES; OSTEOARTHRITIS; PROTEOGLYCANS; RABBITS; RECOMBINANT PROTEINS; UMBELLIFERONES;

EID: 0032983177     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Nagase H, Woessner JF Jr. Role of endogenous proteinases in the degradation of cartilage matrix. In: Woessner JF Jr, Howell DS, editors. Joint cartilage degradation, New York: Marcel Dekker; 1993:159-85.
2. Dodge GR, Poole AR. Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal, rheumatoid, and osteoarthritic cartilages and in explants of bovine articular cartilage cultured with interleukin I. J Clin Invest 1989;83:647-61.
3. Yu LP Jr, Smith GN Jr, Brandt KD, Capello W. Type XI collagen-degrading activity in human osteoarthritic cartilage. Arthritis Rheum 1990;33:1626-33.
4. Martel-Pelletier J, Pelletier JP, Cloutier JM, Howell DS, Ghandur-Mnaymneh L, Woessner JF. Neutral proteases capable of proteoglycan digesting activity in osteoarthritic and normal human articular cartilage. Arthritis Rheum 1984;27:305-12.
5. Mohtai M, Smith RL, Schurman DJ, et al. Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1. J Clin Invest 1993;92:179-85.
6. Mitchell PG, Magna HA, Reeves LM, et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 1996;97:761-8.
7. Okada Y. Shinmei M, Tanaka O, et al. Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Lab Invest 1992;66:680-90.
8. Werb Z. The biologic role of metalloproteinases and their inhibitors. In: Kuettner KE, editor. Articular cartilage and osteoarthritis. New York: Raven Press; 1992;295-304.
9. Lefebvre V, Peeters-Joris C, Vaes G. Modulation by interleukin 1 and tumor necrosis factor alpha of production of collagenase, tissue inhibitor of metalloproteinases and collagen types in differentiated and dedifferentiated articular chondrocytes. Biochim Biophys Acta 1990;1052:366-78.
10. Shinmei M, Masuda K, Kikuchi T, Shimomura Y. Interleukin 1, tumor necrosis factor, and interleukin 6 as mediator of cartilage destruction. Semin Arthritis Rheum 1989;18 Suppl 1:27-32.
11. Tubaro A, Del Negro P, Ragazzi E, Zampiron S, Loggia R. Anti-inflammatory and peripheral analgesic activity of esculetin in vivo. Pharmacol Res Comm 1988;20:83-5.
12. Hascall VC, Handley CJ, McQuillan DJ, Hascall GK, Robinson HC, Lowther DA. Effect of serum on biosynthesis of proteoglycans by bovine articular cartilage in culture. Arch Biochem Biophys 1983;224:206-23.
13. Farndale RW, Sayers CA, Barrett AJ. A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res 1982;9:247-8.
14. Nagai Y, Hori H, Hattori S, et al. A micro-assay method of collagenase activity and its application in the study of collagen metabolism in pathological tissues [in Japanese]. Jpn J Inflammation 1984;4:123-30.
15. Colombo C, Butler M, O'Byrne E, et al. A new model of osteoarthritis in rabbits. I. Development of knee joint pathology following lateral meniscectomy and section of fibular collateral and sesamoid ligaments. Arthritis Rheum 1983;26:875-86.
16. Kikuchi T, Yamada H, Shinmei M. Effect of high molecular weight hyaluronan on cartilage degeneration in a rabbit model of osteoarthritis. Osteoarthritis Cartilage 1996;4:99-110.
17. Shinmei M, Okada Y, Masuda K, et al. The mechanism of cartilage degradation in osteoarthritic joint. Semin Arthritis Rheum 1990;19 Suppl 1:16-20.
18. Ishizue KK, Ehrlich MG, Mankin HJ. Drug-induced inhibition of proteoglycanase activity in the Hulth-Telhag model. J Orthop Res 1989;7:806-11.
19. Ehrlich MG, Stefanich R, Ishizue KK, Armstrong AL, Mankin HJ. In vitro and in vivo effects of metal dictators on cartilage metabolism. J Orthop Res 1990;8:72-7.
20. Yu LP Jr, Smith GN, Brandt KD, Myers SL, O'Connor BL. Brandt DA. Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum 1992;35:1150-9.
21. Ghosh P, Armstrong S, Read R, Numerate Y, McNair P, Marshall R. Animal models of early osteoarthritis: their use for the evaluation of potential chondroprotective agents. Agents Actions 1993; 39:195-206.
22. O'Byrne EM, Parker DT, Robert ED, et al. Oral administration of a matrix metalloproteinase inhibitor, CGS 27023A, protects the cartilage proteoglycan matrix in a partial meniscectomy model of osteoarthritis in rabbits. Inflamm Res 1995;44 Suppl 2:117-8.
23. Fernandes JC, Martel-Pelletier J, Otterness IG, et al. Effects of Tenidap on canine experimental osteoarthritis. I. Morphologic and metalloproteinase analysis. Arthritis Rheum 1995;38:1290-303.
24. Lohmander LS, Hoerrner LA, Lark MW. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 1993;36:181-9.
25. Smith RL, Allison AC, Schurman DJ. Induction of articular cartilage degradation by recombinant interleukin 1α and ß. Connect Tissue Res 1989;18:307-16.
26. Aydelotte MB, Raiss RX, Caterson B, Kuettner KE. Influence of interleukin-1 on the morphology and proteoglycan metabolism of cultured bovine articular chondrocytes. Connect Tissue Res 1992;28:143-59.
27. Mehraban F, Kuo SY, Riera H, Chang C, Moskowitz RW. Prostromelysin and procollagenase genes are differentially upregulated in chondrocytes from the knees of rabbits with experimental osteoarthritis. Arthritis Rheum 1994;37:1189-97.